Vivien Hébert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vivien Hébert has a total of 235 co-authors. Here are the top co-authors by number of shared publications:
- Pascal Joly
Department of Dermatology, Rouen University Hospital, INSERM U1234 Normandie University , Rouen
12 shared publications Pascal Joly
Department of Dermatology, Centre Hospitalier Universitaire de Rouen and Institut National de la Santé et de la Recherche Médicale (INSERM) U1234, Normandie University, Rouen, France
9 shared publications- Marie Petit
Université de Rouen Normandie, Inserm U1234, F-76000 Rouen, France
5 shared publications - Marie-Laure Golinski
Univ Rouen Normandie, Inserm, Normandie Univ, PANTHER UMR 1234, CHU Rouen, Department of Dermatology, F-76000 Rouen, France
5 shared publications - Maud Maho-Vaillant
Univ Rouen Normandie, Inserm, Normandie Univ, PANTHER UMR 1234, CHU Rouen, Department of Dermatology, F-76000 Rouen, France
5 shared publications Olivier Boyer
Univ Rouen Normandie, Inserm, Normandie Univ, PANTHER UMR 1234 Rouen France
5 shared publications
Latest Publications
- 18 June 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (11) , 3044-3053.e3
Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus
- 18 June 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (11) , 3044-3053.e3
Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus
- Open Access
- 27 May 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (10) , 1682-1691
Tocilizumab for severe and refractory mucous membrane pemphigoid
Background: Mucous membrane pemphigoid (MMP) is a rare autoimmune blistering disease involving mucous membranes with a potentially devastating fibrosing course. Laryngotracheal and/or oesophageal involvement may lead to life‐threatening complications, while corneal involvement may lead to blindness. Objectives: To characterize the serum cytokine profile of MMP and to evaluate the efficacy of tocilizumab in nine cases of severe MMP according to the serum levels of IL‐6. Methods: Sera from MMP patients were compared to sex‐ and age‐matched healthy donors (HD) and patients with bullous pemphigoid (BP), using two proteomic assays (Olink and Luminex). The Olink assay included 40 MMP, 40 BP and 40 HD sera, and the Luminex assay included 63 MMP, 31 BP and 24 HD sera. Based on these findings, nine patients with severe and refractory MMP received tocilizumab on a compassionate use basis after failure of standard therapies. Results: Proteomic analyses revealed high serum levels of IL‐6, IL‐8, MIP‐1α/CCL3 and MIP‐1β/CCL4 in MMP compared to BP and HD. Patients with MMP who achieved complete remission during follow‐up had lower baseline serum levels of IL‐6 ( p < 0.0001), IL‐8 ( p = 0.0382), MIP‐1α/CCL3 ( p = 0.0005) and MIP‐1β/CCL4 ( p = 0.0009) than those with persistent disease activity. Nine patients with severe and refractory MMP were treated with tocilizumab. Their mean MMPDAI score decreased from 14.8 ± 6.6 to 4.2 ± 3.2 ( p = 0.009). At the last evaluation, seven patients (78%) were in partial remission, one (11%) in complete remission and one (11%) recently treated achieved control of disease activity. Baseline IL‐6 was elevated in five of eight tested patients; all three with normal IL‐6 levels improved clinically. Four non‐severe adverse events were observed (two neutropenias, one thrombocytopenia, one hepatic cytolysis). Conclusions: Proteomic analyses identified a distinct MMP cytokine profile with increased IL‐6, IL‐8, MIP‐1α/CCL3 and MIP‐1β/CCL4, supporting IL‐6 targeting, with tocilizumab as a potential option in severe refractory MMP.
- 27 May 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (10) , 1682-1691
Open AccessTocilizumab for severe and refractory mucous membrane pemphigoid
Background: Mucous membrane pemphigoid (MMP) is a rare autoimmune blistering disease involving mucous membranes with a potentially devastating fibrosing course. Laryngotracheal and/or oesophageal involvement may lead to life‐threatening complications, while corneal involvement may lead to blindness. Objectives: To characterize the serum cytokine profile of MMP and to evaluate the efficacy of tocilizumab in nine cases of severe MMP according to the serum levels of IL‐6. Methods: Sera from MMP patients were compared to sex‐ and age‐matched healthy donors (HD) and patients with bullous pemphigoid (BP), using two proteomic assays (Olink and Luminex). The Olink assay included 40 MMP, 40 BP and 40 HD sera, and the Luminex assay included 63 MMP, 31 BP and 24 HD sera. Based on these findings, nine patients with severe and refractory MMP received tocilizumab on a compassionate use basis after failure of standard therapies. Results: Proteomic analyses revealed high serum levels of IL‐6, IL‐8, MIP‐1α/CCL3 and MIP‐1β/CCL4 in MMP compared to BP and HD. Patients with MMP who achieved complete remission during follow‐up had lower baseline serum levels of IL‐6 ( p < 0.0001), IL‐8 ( p = 0.0382), MIP‐1α/CCL3 ( p = 0.0005) and MIP‐1β/CCL4 ( p = 0.0009) than those with persistent disease activity. Nine patients with severe and refractory MMP were treated with tocilizumab. Their mean MMPDAI score decreased from 14.8 ± 6.6 to 4.2 ± 3.2 ( p = 0.009). At the last evaluation, seven patients (78%) were in partial remission, one (11%) in complete remission and one (11%) recently treated achieved control of disease activity. Baseline IL‐6 was elevated in five of eight tested patients; all three with normal IL‐6 levels improved clinically. Four non‐severe adverse events were observed (two neutropenias, one thrombocytopenia, one hepatic cytolysis). Conclusions: Proteomic analyses identified a distinct MMP cytokine profile with increased IL‐6, IL‐8, MIP‐1α/CCL3 and MIP‐1β/CCL4, supporting IL‐6 targeting, with tocilizumab as a potential option in severe refractory MMP.
- 10 April 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (9)
Baricitinib and low‐dose prednisone for very severe alopecia areata: A retrospective case series
- 10 April 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (9)
Baricitinib and low‐dose prednisone for very severe alopecia areata: A retrospective case series
- 6 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Analyse des réponses lymphocytaires B et T spécifiques de l'antigène des patients atteints de pemphigus et traités par rituximab.
Le traitement de 1ère intention des formes modérée à sévère de pemphigus vulgaire (PV) est le RTX, un Ac monoclonal chimérique anti-CD20, associé à une corticothérapie orale de courte durée. Malgré l’efficacité redoutable de cette association, un taux de rechutes important persiste, principalement la 1ère année.D’abord, nous avons déterminé des facteurs pronostiques de rechute chez les patients traités par RTX. La présence d’au moins un des critères suivants : PDAI ≥ 45 au diagnostic et/ou la présence d’Ac anti-DSG1 ≥ 20UI/mL et/ou anti-DSG3 ≥ 130UI/mL entre le 3ème et le 6ème mois permettait de prédire une rechute à court terme avec une VPP de 50% et une VPN de 94%.Ensuite, une analyse transcriptomique longitudinale sur 33 gènes d’intérêt a montré que les LB autoréactifs présentaient initialement un profil pro-inflammatoire par rapport aux LB non auto-réactifs, marquée par la surexpression de 3 gènes codant pour les cytokines IL-1β, IL-12p35 et IL-23p19 ainsi que pour le gène de l’IRF5. Étonnamment, le rituximab n’induisait que peu de changement d’expression génique, à l'exception de l’IL-1β et du CD27 tous deux « down-régulés ». La diminution d’expression du marqueur mémoire CD27 était confirmée en cytométrie, et corrélée à l’amélioration clinique.Par la suite, nous avons étudié la cytokine BAFF et son récepteur BAFF-R. Nous avons montré que les taux sériques basaux de BAFF étaient plus élevés chez les patients atteints de pemphigus que chez les donneurs sains et plus particulièrement chez les rechuteurs. Le rituximab entraînait une augmentation des taux de BAFF associée à une diminution d’expression transcriptomique et cytométrique de BAFF-R à la fois sur les LB non-autoréactifs et autoréactifs. La CS permettait une diminution transitoire de BAFF suivie d’une ré-ascension lors de la décroissance sous un seuil de 20mg/j, sans modification de l’expression de BAFF-R. Ainsi, l'activation des LB autoréactifs au début du pemphigus pourrait être liée à la présence de taux sériques élevés de BAFF et la diminution de l'expression du BAFF-R retarderait le retour de cellules B mémoires. Inversement, la déplétion incomplète des cellules B et l'expression persistante de BAFF-R associées à une ré ascension de BAFF pourraient expliquer les rechutes chez les patients traités par CS.Dans un autre travail, nous avons étudié la distribution et l'évolution des sous-classes d'IgG anti-DSG3 chez les patients atteints de PV et corrélé leur distribution et leur pathogénicité in vitro avec l'évolution clinique des patients, avant et après CS seule ou associée au RTX. Nous avons confirmé la présence majoritaire d’IgG4 anti-DSG3 chez les patients, avec une association à une autre sous-classe dans 1/4 des cas. Le RTX permettait de réduire la diversité des sous-classes. La présence de ≥2 sous-classes d'IgG anti-DSG3 au diagnostic était liée à un risque accru de rechute. Nos tests de pathogénicité ont souligné l’importance de la concentration en IgG4 anti-DSG3, principalement lorsqu’il s’agit du seul isotype retrouvé. Au contraire, dans le cas de patients présentant à la fois des IgG3 et des IgG4 au diagnostic et uniquement des IgG4 en rémission, les IgG3 purifiées ont été capables d'induire une acantholyse alors que les résidus purifiés d'IgG3 ne l'étaient pas. nfin, nous avons étudié l’impact du RTX sur la fréquence, la polarisation et l’activation des LT folliculaires helper (Tfh) et régulateurs (Tfr) spécifiques de la DSG3. Au diagnostic, nous avons montré que les phénotypes des Tfh autoréactifs et non autoréactifs des patients étaient différents avec une prédominance des phénotypes Tfh1* et Tfh17 dans les Tfh autoréactifs et, au contraire, un phénotype Tfh2 sous-représenté. Le RTX n'avait aucun effet sur la polarisation des Tfh. Nous avons ensuite démontré l'émergence d'une population Tfr spécifique de l'Ag après l'utilisation de RTX. De plus, ces Tfr surexprimaient significativement les marqueurs d'activation de surface PD1, ICOS et CD25.
- 6 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Analyse des réponses lymphocytaires B et T spécifiques de l'antigène des patients atteints de pemphigus et traités par rituximab.
Le traitement de 1ère intention des formes modérée à sévère de pemphigus vulgaire (PV) est le RTX, un Ac monoclonal chimérique anti-CD20, associé à une corticothérapie orale de courte durée. Malgré l’efficacité redoutable de cette association, un taux de rechutes important persiste, principalement la 1ère année.D’abord, nous avons déterminé des facteurs pronostiques de rechute chez les patients traités par RTX. La présence d’au moins un des critères suivants : PDAI ≥ 45 au diagnostic et/ou la présence d’Ac anti-DSG1 ≥ 20UI/mL et/ou anti-DSG3 ≥ 130UI/mL entre le 3ème et le 6ème mois permettait de prédire une rechute à court terme avec une VPP de 50% et une VPN de 94%.Ensuite, une analyse transcriptomique longitudinale sur 33 gènes d’intérêt a montré que les LB autoréactifs présentaient initialement un profil pro-inflammatoire par rapport aux LB non auto-réactifs, marquée par la surexpression de 3 gènes codant pour les cytokines IL-1β, IL-12p35 et IL-23p19 ainsi que pour le gène de l’IRF5. Étonnamment, le rituximab n’induisait que peu de changement d’expression génique, à l'exception de l’IL-1β et du CD27 tous deux « down-régulés ». La diminution d’expression du marqueur mémoire CD27 était confirmée en cytométrie, et corrélée à l’amélioration clinique.Par la suite, nous avons étudié la cytokine BAFF et son récepteur BAFF-R. Nous avons montré que les taux sériques basaux de BAFF étaient plus élevés chez les patients atteints de pemphigus que chez les donneurs sains et plus particulièrement chez les rechuteurs. Le rituximab entraînait une augmentation des taux de BAFF associée à une diminution d’expression transcriptomique et cytométrique de BAFF-R à la fois sur les LB non-autoréactifs et autoréactifs. La CS permettait une diminution transitoire de BAFF suivie d’une ré-ascension lors de la décroissance sous un seuil de 20mg/j, sans modification de l’expression de BAFF-R. Ainsi, l'activation des LB autoréactifs au début du pemphigus pourrait être liée à la présence de taux sériques élevés de BAFF et la diminution de l'expression du BAFF-R retarderait le retour de cellules B mémoires. Inversement, la déplétion incomplète des cellules B et l'expression persistante de BAFF-R associées à une ré ascension de BAFF pourraient expliquer les rechutes chez les patients traités par CS.Dans un autre travail, nous avons étudié la distribution et l'évolution des sous-classes d'IgG anti-DSG3 chez les patients atteints de PV et corrélé leur distribution et leur pathogénicité in vitro avec l'évolution clinique des patients, avant et après CS seule ou associée au RTX. Nous avons confirmé la présence majoritaire d’IgG4 anti-DSG3 chez les patients, avec une association à une autre sous-classe dans 1/4 des cas. Le RTX permettait de réduire la diversité des sous-classes. La présence de ≥2 sous-classes d'IgG anti-DSG3 au diagnostic était liée à un risque accru de rechute. Nos tests de pathogénicité ont souligné l’importance de la concentration en IgG4 anti-DSG3, principalement lorsqu’il s’agit du seul isotype retrouvé. Au contraire, dans le cas de patients présentant à la fois des IgG3 et des IgG4 au diagnostic et uniquement des IgG4 en rémission, les IgG3 purifiées ont été capables d'induire une acantholyse alors que les résidus purifiés d'IgG3 ne l'étaient pas. nfin, nous avons étudié l’impact du RTX sur la fréquence, la polarisation et l’activation des LT folliculaires helper (Tfh) et régulateurs (Tfr) spécifiques de la DSG3. Au diagnostic, nous avons montré que les phénotypes des Tfh autoréactifs et non autoréactifs des patients étaient différents avec une prédominance des phénotypes Tfh1* et Tfh17 dans les Tfh autoréactifs et, au contraire, un phénotype Tfh2 sous-représenté. Le RTX n'avait aucun effet sur la polarisation des Tfh. Nous avons ensuite démontré l'émergence d'une population Tfr spécifique de l'Ag après l'utilisation de RTX. De plus, ces Tfr surexprimaient significativement les marqueurs d'activation de surface PD1, ICOS et CD25.
- 10 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1182-1184
Prevalence and pathogenicity of anti-SPCA1 and anti-M3AchR autoantibodies in pemphigus
Anti-muscarinic-acetylcholine-receptor-subtype-M3 (anti-M3AchR) and anti-secretory-pathway-Ca2+/Mn2+-ATPase-isoform-1 (anti-SPCA1) autoantibodies have been suggested as potential targets in pemphigus. However, their role during the course of pemphigus remains poorly characterized. The objective of the study was to determine the frequency, evolution and pathogenicity of anti-SPCA1 and anti-M3AchR autoantibodies in pemphigus. Anti-SPCA1 and anti-M3AchR IgG were detected in almost one-third of sera from patients with pemphigus. We demonstrated their in vitro pathogenic activity, alone or in combination. Anti-SPCA1 and anti-M3AchR autoantibodies were associated with a higher risk of relapse and may help clinicians in patient management.
- 10 March 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1182-1184
Prevalence and pathogenicity of anti-SPCA1 and anti-M3AchR autoantibodies in pemphigus
Anti-muscarinic-acetylcholine-receptor-subtype-M3 (anti-M3AchR) and anti-secretory-pathway-Ca2+/Mn2+-ATPase-isoform-1 (anti-SPCA1) autoantibodies have been suggested as potential targets in pemphigus. However, their role during the course of pemphigus remains poorly characterized. The objective of the study was to determine the frequency, evolution and pathogenicity of anti-SPCA1 and anti-M3AchR autoantibodies in pemphigus. Anti-SPCA1 and anti-M3AchR IgG were detected in almost one-third of sera from patients with pemphigus. We demonstrated their in vitro pathogenic activity, alone or in combination. Anti-SPCA1 and anti-M3AchR autoantibodies were associated with a higher risk of relapse and may help clinicians in patient management.
- Open Access
- 7 March 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (10) , 1675-1681
Incidence of P200 pemphigoid: A nationwide study
Background: Anti‐p200 pemphigoid (P200) is a rare subepidermal autoimmune blistering disease (AIBD) related to anti‐laminin γ1 autoantibodies (Abs). It has been recently reported that laminin β4 was frequently recognized by sera from patients with P200. Objectives: To evaluate the incidence of P200 in France using a new recombinant anti‐laminin β4 serological assay. Methods: This multicentre retrospective study was conducted in the Immunology Laboratory of the French reference centre for AIBD from January 2018 to March 2023. Sera suspected of corresponding to P200 were tested using the new anti‐LAMB4 cell‐based immunoassay (CBIA) and/or immunoblotting (IB) on dermal extract. The incidence of P200 was then estimated based on its incidence rate relative to those of BP and pemphigus over the same period. Results: 116 patients with sera labelling the dermal side of salt‐split skin by IIF and negative for other junctional AIBD were recorded. Among them, 23 patients' sera had already been tested positive for P200 by dermal IB. Thus, 93 patients' sera were tested with both the anti‐LAMB4 CBIA and IB: 85 were positive with the CBIA (91%) vs. 44 with IB (47%, p < 0.0001). Only two were positive with IB alone. Overall, 110 patients had anti‐p200 Abs. Subsequently, we compared the frequency of serological detection of P200 to that of BP and pemphigus based on data from centres that exhaustively submitted their sera to our reference laboratory. According to the incidence of BP and pemphigus in France (21.7 and 1.85 cases per million inhabitants per year, respectively), the incidence of P200 was estimated to range from 0.23 to 0.83 cases per million inhabitants per year. This corresponds to approximately 16–57 new cases annually in France, which is approximately 2‐ to 4‐fold more frequent than epidermolysis bullosa acquisita . Conclusions: This study shows that P200 may be much more frequent than initially estimated.
- 7 March 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (10) , 1675-1681
Open AccessIncidence of P200 pemphigoid: A nationwide study
Background: Anti‐p200 pemphigoid (P200) is a rare subepidermal autoimmune blistering disease (AIBD) related to anti‐laminin γ1 autoantibodies (Abs). It has been recently reported that laminin β4 was frequently recognized by sera from patients with P200. Objectives: To evaluate the incidence of P200 in France using a new recombinant anti‐laminin β4 serological assay. Methods: This multicentre retrospective study was conducted in the Immunology Laboratory of the French reference centre for AIBD from January 2018 to March 2023. Sera suspected of corresponding to P200 were tested using the new anti‐LAMB4 cell‐based immunoassay (CBIA) and/or immunoblotting (IB) on dermal extract. The incidence of P200 was then estimated based on its incidence rate relative to those of BP and pemphigus over the same period. Results: 116 patients with sera labelling the dermal side of salt‐split skin by IIF and negative for other junctional AIBD were recorded. Among them, 23 patients' sera had already been tested positive for P200 by dermal IB. Thus, 93 patients' sera were tested with both the anti‐LAMB4 CBIA and IB: 85 were positive with the CBIA (91%) vs. 44 with IB (47%, p < 0.0001). Only two were positive with IB alone. Overall, 110 patients had anti‐p200 Abs. Subsequently, we compared the frequency of serological detection of P200 to that of BP and pemphigus based on data from centres that exhaustively submitted their sera to our reference laboratory. According to the incidence of BP and pemphigus in France (21.7 and 1.85 cases per million inhabitants per year, respectively), the incidence of P200 was estimated to range from 0.23 to 0.83 cases per million inhabitants per year. This corresponds to approximately 16–57 new cases annually in France, which is approximately 2‐ to 4‐fold more frequent than epidermolysis bullosa acquisita . Conclusions: This study shows that P200 may be much more frequent than initially estimated.
- 1 March 2026
- Published by JLE in Dermato Mag
- Vol. 14 (S3) , 9-13
Description et diagnostic des différentes formes cliniques de la pelade
- 1 March 2026
- Published by JLE in Dermato Mag
- Vol. 14 (S3) , 9-13
Description et diagnostic des différentes formes cliniques de la pelade
- 1 April 2025
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 161 (4) , 399-405
Optimizing Pemphigus Management With Rituximab and Short-Term Relapse Predictors
Importance: Rituximab is approved for the treatment of moderate to severe pemphigus. However, 20% of patients in the RITUX 3 trial relapsed within the first year of treatment.Objective: To assess the outcome of an additional rituximab infusion at month 6 in patients with pemphigus who were in complete remission (CR) after rituximab regimen but had 1 or more predictors of relapse at month 3.Design, Settings, and Participants: This multicenter cohort study was conducted in France from September 2018 to June 2023 to assess patients with newly diagnosed pemphigus who were in CR after treatment with the RITUX 3 regimen but had predictors of relapse at month 3. Relapse factors were a Pemphigus Disease Area Index (PDAI) score of 45 or higher, desmoglein 1 (DSG1) antibodies greater than 20 IU/mL, and/or DSG3 antibodies greater than 130 IU/mL.Exposure: Patients in CR at month 6 with at least 1 predictor of relapse were treated with an additional rituximab infusion at month 6.Main Outcomes and Measures: Primary end point was the rate of CR without corticosteroid therapy for 2 months at month 12. Secondary end points were the rate of relapse, number of patients needing to be re-treated (NNT) with rituximab to avoid a relapse, and safety.Results: The study population comprised 87 patients (44 females [50.6%] and 43 [49.4%] males), with a mean (SD [range]) age of 55.3 (15.2 [24-92]) years at pemphigus diagnosis. Of these, 64 patients (73.6%) had pemphigus vulgaris and 23 (26.4%) had pemphigus foliaceus. At month 6, CR had been achieved by 77 patients (88.5%), and 10 (11.5%) had persistent disease activity. Of the 77 patients in CR, 30 (39.0%) had at least 1 predictor of relapse and received an additional infusion of rituximab; 47 patients (61.0%) without a predictor did not. Two patients without a predictor and no patients with a predictor experienced relapse—an overall relapse rate of 2.6% and an NNT of 3.6 (95% CI, 1.6-46.5). The 10 patients (11.5%) with persistent disease activity at month 6 were re-treated with rituximab, 2000 mg. At month 12, the rate of CR without corticosteroid therapy for a minimum of 2 months was 72 of 77 (93.5%) among patients who had achieved CR at month 6, and 72 of 87 (82.7%) for the whole study population. Eight serious adverse effects were reported among 5 patients; there were no deaths.Conclusion and Relevance: This multicenter cohort study indicates that using predictors such as baseline PDAI score, anti-DSG1 antibodies, and/or anti-DSG3 antibodies to initiate preemptive treatment with additional rituximab may reduce the rate of short-term relapse.
- 1 April 2025
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 161 (4) , 399-405
Optimizing Pemphigus Management With Rituximab and Short-Term Relapse Predictors
Importance: Rituximab is approved for the treatment of moderate to severe pemphigus. However, 20% of patients in the RITUX 3 trial relapsed within the first year of treatment.Objective: To assess the outcome of an additional rituximab infusion at month 6 in patients with pemphigus who were in complete remission (CR) after rituximab regimen but had 1 or more predictors of relapse at month 3.Design, Settings, and Participants: This multicenter cohort study was conducted in France from September 2018 to June 2023 to assess patients with newly diagnosed pemphigus who were in CR after treatment with the RITUX 3 regimen but had predictors of relapse at month 3. Relapse factors were a Pemphigus Disease Area Index (PDAI) score of 45 or higher, desmoglein 1 (DSG1) antibodies greater than 20 IU/mL, and/or DSG3 antibodies greater than 130 IU/mL.Exposure: Patients in CR at month 6 with at least 1 predictor of relapse were treated with an additional rituximab infusion at month 6.Main Outcomes and Measures: Primary end point was the rate of CR without corticosteroid therapy for 2 months at month 12. Secondary end points were the rate of relapse, number of patients needing to be re-treated (NNT) with rituximab to avoid a relapse, and safety.Results: The study population comprised 87 patients (44 females [50.6%] and 43 [49.4%] males), with a mean (SD [range]) age of 55.3 (15.2 [24-92]) years at pemphigus diagnosis. Of these, 64 patients (73.6%) had pemphigus vulgaris and 23 (26.4%) had pemphigus foliaceus. At month 6, CR had been achieved by 77 patients (88.5%), and 10 (11.5%) had persistent disease activity. Of the 77 patients in CR, 30 (39.0%) had at least 1 predictor of relapse and received an additional infusion of rituximab; 47 patients (61.0%) without a predictor did not. Two patients without a predictor and no patients with a predictor experienced relapse—an overall relapse rate of 2.6% and an NNT of 3.6 (95% CI, 1.6-46.5). The 10 patients (11.5%) with persistent disease activity at month 6 were re-treated with rituximab, 2000 mg. At month 12, the rate of CR without corticosteroid therapy for a minimum of 2 months was 72 of 77 (93.5%) among patients who had achieved CR at month 6, and 72 of 87 (82.7%) for the whole study population. Eight serious adverse effects were reported among 5 patients; there were no deaths.Conclusion and Relevance: This multicenter cohort study indicates that using predictors such as baseline PDAI score, anti-DSG1 antibodies, and/or anti-DSG3 antibodies to initiate preemptive treatment with additional rituximab may reduce the rate of short-term relapse.
- 8 June 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (4) , 605-615
The emergence of circulating activated autoreactive desmoglein 3-specific follicular regulatory T cells is associated with long-term efficacy of rituximab in patients with pemphigus vulgaris
Background: Pemphigus vulgaris (PV) is characterized by autoantibodies targeting keratinocyte adhesion proteins desmoglein (Dsg) 1 and 3, and by the human leukocyte antigen (HLA) predisposition allele HLA-DRB1*0402. Treatment using rituximab (RTX) combined with short-term corticosteroids (CS) allows disease control and long-lasting remission. Objectives: The principal aim of this study was to evaluate the impact of RTX on the circulating subpopulations of Dsg3-specific T lymphocytes that specifically regulate B-cell responses: follicular helper T (Tfh) and follicular regulatory T (Tfr) lymphocytes. Methods: Using the HLA-DRB1*0402 tetramer loaded with the Dsg3 immunodominant peptide, we used flow cytometry to analyse the frequency, polarization and activation status of blood Dsg3-specific follicular T-cell populations at baseline, month (M) 6 and long-term follow-up (M60–90) from patients with PV. Results: At baseline, we observed a predominance of Tfh1* and Tfh17 subsets and an underrepresentation of the Tfh2 subset among autoreactive Dsg3-specific Tfh cells compared with nonautoreactive Tfh cells. RTX treatment induced a decrease of autoreactive Tfh cells with no effect on their polarization during follow-up. In parallel, we observed the emergence of a Dsg3-specific Tfr subpopulation with a significant overexpression of the surface activation markers PD1, ICOS and CD25 that was not observed at the surface of autoreactive Tfh and nonautoreactive Tfr cells of the same patients with PV. In contrast, very few Dsg3-specific Tfr cells were observed in patients with PV who were treated with CS alone. Conclusions: Here we show that the emergence of circulating autoreactive Dsg3-specific Tfr cells is associated with the long-term efficacy of RTX in patients with PV. Graphical
- 8 June 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (4) , 605-615
The emergence of circulating activated autoreactive desmoglein 3-specific follicular regulatory T cells is associated with long-term efficacy of rituximab in patients with pemphigus vulgaris
Background: Pemphigus vulgaris (PV) is characterized by autoantibodies targeting keratinocyte adhesion proteins desmoglein (Dsg) 1 and 3, and by the human leukocyte antigen (HLA) predisposition allele HLA-DRB1*0402. Treatment using rituximab (RTX) combined with short-term corticosteroids (CS) allows disease control and long-lasting remission. Objectives: The principal aim of this study was to evaluate the impact of RTX on the circulating subpopulations of Dsg3-specific T lymphocytes that specifically regulate B-cell responses: follicular helper T (Tfh) and follicular regulatory T (Tfr) lymphocytes. Methods: Using the HLA-DRB1*0402 tetramer loaded with the Dsg3 immunodominant peptide, we used flow cytometry to analyse the frequency, polarization and activation status of blood Dsg3-specific follicular T-cell populations at baseline, month (M) 6 and long-term follow-up (M60–90) from patients with PV. Results: At baseline, we observed a predominance of Tfh1* and Tfh17 subsets and an underrepresentation of the Tfh2 subset among autoreactive Dsg3-specific Tfh cells compared with nonautoreactive Tfh cells. RTX treatment induced a decrease of autoreactive Tfh cells with no effect on their polarization during follow-up. In parallel, we observed the emergence of a Dsg3-specific Tfr subpopulation with a significant overexpression of the surface activation markers PD1, ICOS and CD25 that was not observed at the surface of autoreactive Tfh and nonautoreactive Tfr cells of the same patients with PV. In contrast, very few Dsg3-specific Tfr cells were observed in patients with PV who were treated with CS alone. Conclusions: Here we show that the emergence of circulating autoreactive Dsg3-specific Tfr cells is associated with the long-term efficacy of RTX in patients with PV. Graphical